What Happened

Syndax Pharmaceuticals presented clinical data for Revuforj (revumenib) at the EHA 2026 Congress, demonstrating its efficacy in treating acute leukemia with specific mutations. Key findings included a 97% composite complete remission rate in a Phase 1 trial and strong real-world performance in relapsed/refractory cases.

Who Is Affected

Hematologists, oncologists, and healthcare providers treating acute leukemia patients, particularly those with NPM1 mutations or KMT2A rearrangements, are directly impacted. Patients with relapsed/refractory disease or those undergoing post-transplant maintenance also benefit.

Market Impact

• Revuforj strengthens Syndax's position in the acute leukemia market.
• Its efficacy as a post-transplant maintenance therapy opens new treatment pathways.
• Real-world data supports its adoption in clinical practice.

What to Watch

Monitor ongoing trials and real-world studies for long-term efficacy and safety data. Watch for updates on Revuforj's integration into treatment guidelines and its adoption in post-transplant care.